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Abstract
Background: The most common reason for malignant tumor treatment failure is recurrence and metastasis.
Metastasis-associated in colon cancer-1 (MACC1) was originally identified as a metastatic and prognostic biomarker
for colon cancer and later other solid tumors. Kangai 1 (KAI1), a marker of suppressor of metastasis, is also
associated with metastasis and poor prognosis in many tumors. However, the prognostic value of either MACC1 or
KAI1 in gastric adenocarcinoma (GAC) is unclear. In this study, we explored the relationship between MACC1 and
KAI1 expression, as well as their respective correlation with clinicopathological features, to determine if either could
be helpful for improvement of survival prognosis in GAC patients.
Methods: The expression levels of both MACC1 and KAI1 in 325 whole-tissue sections of GAC were examined by
immunohistochemistry. Clinical data was also collected.
Results: MACC1 was significantly overexpressed in GAC tissues when compared to levels in normal gastric tissues;
KAI1 was significantly down-expressed in GAC tissues when compared to levels in normal gastric tissues.
Investigation of association between MACC1 and KAI1 protein levels with clinicopathological parameters of GAC
indicated association between the expression of each with tumor grade, lymph node metastasis, invasive depth,
and TNM stages. The overall survival time of patients with MACC1- or KAI1-positive GAC tumors was significantly
shorter or longer than that of those who were negative. Importantly, multivariate analysis suggested that positive
expression of either MACC1 or KAI1, as well as TNM stage, could be independent prognostic factors for overall
survival in patients with GAC.
Conclusions: MACC1 and KAI1 may represent promising metastatic and prognostic biomarkers, as well as potential
therapeutic targets, for GAC.
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Background
There were approximately 950,000 new stomach cancer
cases and 720,000 deaths that occurred in 2012 world-
wide [1]. In general, China is one of the highest inci-
dence countries worldwide [1]. Gastric adenocarcinoma
(GAC) accounts for approximately 90 % of all diagnosed
stomach cancers. It was also one of the most frequent
causes of cancer-related deaths. The 5-year survival rate
is less than 5 % for GAC patients with distant metastasis,
as well as is less than 60 % for patients with only local-
ized malignancies [2]. In China, the majority of patients
diagnosed with GAC have advanced stages of disease
and are unsuitable for curative surgery.
Tumor recurrence and metastasis are the most common
cause of treatment failure. Tumor recurrence and metas-
tasis involve in multiple steps with a high degree of
complexity and require the contribution of many mole-
cules. Metastasis-associated in colon cancer-1 (MACC1)
is a gene which contributes to these processes. MACC1
was first identified in colon cancer in 2009 and was bound
to the promoter of the mesenchymal-epithelial transition
(MET) gene to control its transcriptional activity [3, 4]. In
vitro, MACC1 may drive proliferation, migration, inva-
sion, and dissemination [5]; in vivo, it may regulate gene
transcriptionally for metastasis, such as tyrosine kinase
MET [5–7]. Furthermore, accumulating evidence has
indicated that MACC1 should contribute to apoptosis and
epithelial-mesenchymal transition (EMT) via hepatocyte
growth factor/mesenchymal-epithelial transition (HGF/
MET) pathways [8]. MACC1 was also considered as a de-
cisive driver for metastasis and tumorigenesis [9]. MACC1
was also an independent prognostic factor for colon can-
cer [3, 5]. Now, more and more studies have demonstrated
that MACC1 could also be a metastatic and prognostic
factor for various human cancers, including pancreatic
[10], liver [11], lung [12], ovary [13], breast [14], gastric
[8], malignant glioma [15], and cervical carcinoma [16].
Kangai 1 (KAI1) was first identified as a suppressor of
metastasis gene in prostate carcinoma [17]. KAI1
protein which is located in human chromosome 11p11.2
is a member of the transmembrane 4 superfamily
(TM4SF). KAI1 can regulate signal transduction both
cells to cells and cells to extracellular matrix (ECM) [18]
and involve in some fundamental biological processes
such as fusion, migration, adhesion, fertilization, differ-
entiation, and invasion [19, 20]. Accumulating evidence
has demonstrated that decreased or lost KAI1 expres-
sion should associate with metastasis and prognosis in
various tumors, including laryngeal carcinoma [20],
prostate carcinoma [19, 21], breast carcinoma [22], lung
carcinoma [23], gastric carcinoma [24], colon carcinoma
[25], and hepatocellular carcinoma [26].
The involvement of MACC1 and KAI1 in the recur-
rence and metastasis of GAC suggests that they should
be valuable biomarkers for measuring cancer progres-
sion and developing higher accurately therapeutic tar-
gets. To our knowledge, a correlation between MACC1
and KAI1 in GAC has not yet been reported. In this
study, we detected the association between MACC1 and
KAI1 expression in patient cancer tissues as well as
compared their expression with clinicopathology, metas-
tasis, and prognosis of GAC.
Methods
Biopsy specimens
GAC tissues and adjacent noncancerous gastric tissues
were collected at the Department of Pathology of the First
Affiliated Hospital of Bengbu Medical College, from
January 2008 to December 2010. Patients who had received
preoperative chemo- or radio-therapy were excluded. All
tissue specimens were obtained with patient consent, and
the research was approved by the ethical committee of
Bengbu Medical College and conducted in accordance with
the ethical guidelines of the Declaration of Helsinki. The
adjacent noncancerous gastric tissues were removed from
the same patient, avoiding necrotic tissue, and from
surrounding gastric tissue at least 5 cm away from the
carcinoma edge. The research group consisted of 325
patients, 214 males and 111 females, aged from 26 to
78 years; the average age was 57.7 ± 10.9 years. All patients
who had completely clinical, pathological, and follow-up
(at 8-month intervals by phone, mail, or email) data were
sporadic cases. Overall survival (OS) time was collected
from surgery to death or December 2015 (mean OS time
42.0 months; range 8–95 months). Tumor node metastasis
stage was evaluated according to the 7th edition of the
American Joint Committee on Cancer (AJCC). Grade of
tumor differentiation was according to the World Health
Organization (WHO) standard.
Please contact author for data requests.
Immunohistochemistry
All GAC and corresponding normal gastric tissues were
fixed in 10 % buffered formalin and embedded in paraf-
fin. Then continuous 4-μm-thick tissue sections were
cut. Subsequently, all sections were deparaffinized and
dehydrated with xylene, graded ethanol, and washed for
10 min in PBS (pH 7.2). Immunohistochemistry was
performed according to the Elivision Plus detection kit
instructions (Lab Vision, USA). Endogenous peroxidase
activity was blocked by incubation of sections in
methanol containing 3 % H2O2 for 10 min at room
temperature, then placed in citrate buffer (pH 6.0) and
heated to 95 °C for 30 min for antigen repair. After sev-
eral washes in PBS, the sections were quenched with
goat serum for 20 min at room temperature, then
incubated with rabbit polyclonal antibody against human
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MACC1 (Santa Cruz Biotechnology, Santa Cruz, CA,
USA) or mouse monoclonal antibody against human
KAI1 (Abcam, Cambridge, MA, USA) for 1 h at 37 °C.
All sections were counterstained with hematoxylin,
dehydrated, air-dried, and mounted. Negative controls
were prepared by deleting primary antibodies from the
staining procedure. MACC1-positive staining was mainly
confined in the cytoplasm of cancer cells, and KAI1-
positive staining was mainly confined in the membrane
and cytoplasm of cancer cells.
Evaluation of staining
Staining results were evaluated by two experienced
pathologists who were blind to the clinical data and
assessed by semi-quantitative scores. Because of intratu-
moral heterogeneity of antibody expression, we ran-
domly chose ten visual fields from different areas of
each section of GAC. If there was a disagreement, the
pathologists would reexamine the immunostaining and
reach a consensus [27–29]. To assess MACC1 and KAI1
expression, both the extent and intensity of immuno-
staining were thought [27]. The staining extent score
was graded as follows: none, 0; weak, 1; moderate, 2;
and strong, 3. The intensity of positive staining was
graded as follows: <10 %, 1; 11–50 %, 2; 51–75 %, 3; and
>75 %, 4. Then the score was determined by multiplying
the extent and intensity of immunostaining to reach a
range of scores from 0 to 12. For tumors that were posi-
tive for both MACC1 and KAI1, an average of the final
of each sample was taken. Immunostaining was thought
positive when the score was ≥3.
Statistical analysis
Relationship between either MACC1- or KAI1 protein
expression and clinicopathological parameters were
compared using Fisher’s exact test or chi-square test.
The correlation between MACC1 and KAI1 expression
was compared using Spearman’s coefficient test. The ef-
fects of MACC1 and KAI1 expression on OS time were
determined using Kaplan-Meier method for univariate
analysis. Independent prognostic indicators were deter-
mined using the Cox regression model for multivariate
analysis. The association between the positive expression
of either MACC1 or KAI1 and clinicopathological
parameters was determined using SPSS 19.0 software for
Windows (Chicago, IL). A value of P < 0.05 was deter-
mined as statistically significant.
Results
All GAC patient clinicopathological characteristics could
be seen in Table 1.
Expression of MACC1 and KAI1 in GAC and their
association with clinicopathology
To assess the contributions of MACC1 and KAI1 to
GAC, their expression levels were evaluated in both
GAC and normal gastric tissue slides using immunohis-
tochemistry. MACC1-positive staining was mainly con-
fined in the cytoplasm of cancer cells, and KAI1-positive
staining was mainly confined in the membrane and
cytoplasm of cancer cells. These data were compared to
clinicopathological characteristics. The positive rate of
MACC1 protein expression was 60.3 % (196/325) in
Table 1 Patients characteristics
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4.0 cm ≤ D < 8.0 cm 211 64.9
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I and II 153 47.1
III and IV 172 52.9
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GAC tissues and 9.2 % (30/325) in normal gastric tissues
(Fig. 1a, b), and this difference was shown to be statis-
tically significant (P < 0.01). There were also significant
differences between the expression of MACC1 and
tumor grade (P = 0.009), size of tumor (P = 0.009),
invasion of depth (P < 0.001), lymph node metastasis
(LNM) (P < 0.001), and tumor-node-metastasis (TNM)
(P < 0.001). In contrast, there were no associations detected
between MACC1 expression and patient age (P = 0.295),
gender (P = 0.482), location (P = 0.072), and gross type
(P = 0.108).
In contrast to MACC1 expression, the expression of
KAI1 was significantly lower in GAC than in control
tissues, with positive rates of 41.2 % (134/325) and 92.3 %
(300/325), respectively (P < 0.01) (Fig. 1c, d). There were
also negative associations between expression of KAI1 in
GAC and tumor grades (P = 0.045), invasion of depth (P
< 0.001), lymph node metastasis (P = 0.016), and TNM
stage (P < 0.001). There were no relationships detected
between KAI1 expression and patient age (P = 0.079),
gender (P = 0.065), size of tumor (P = 0.354), location
(P = 0.372), and gross type (P = 0.965) (Table 2). Spear-
man correlation coefficient analysis demonstrated a
negative correlation between the expression of MACC1
and KAI1 (r = −0.240, P < 0.001) (Table 2).
Univariate analysis
Follow-up data indicated that overall survival time was
significantly decreased in GAC patients with positive
expression of MACC1 (32.7 months) compared to those
who were MACC1-negative (56.1 months) (log-rank =
46.375, P < 0.001) (Fig. 2a). On the contrast, the OS time
of KAI1-positive patients (52.6 months) was signifi-
cantly longer than those tumors which were negative
(34.5 months) (log-rank = 25.422, P < 0.001) (Fig. 2b). In
the univariate analysis, OS time was significantly
related to clinicopathological characteristics, such as
tumor diameter (P = 0.033, log-rank = 6.844), invasion
of depth (P < 0.001, log-rank = 26.806), LNM (P < 0.001,
log-rank = 75.925), and TNM stage (P < 0.001, log-rank
= 158.587) (Table 3).
Multivariate analysis
Multivariate analysis demonstrated that positive ex-
pression of either MACC1 or KAI1, as well as TNM
stage, was an independent prognostic indicator for GAC
(Table 4).
Discussion
Gastric adenocarcinoma (GAC) is a highly heteroge-
neous tumor. This heterogeneity may affect the reprodu-
cibility of biomarker evaluation [5, 30]. So, thorough
investigation of the metastatic and prognostic values of a
candidate biomarker is thus required to ensure validity.
In our study, we investigated MACC1 expression in
GAC and matched normal tissues from 325 patients and
compared it to clinicopathological characteristics. We
found that MACC1 expression was significantly higher
Fig. 1 Representative results of MACC1 and KAI1 in gastric adenocarcinoma and control group. a Control gastric epithelial cells not expressing
MACC1. b MACC1 predominantly localized in the cytoplasm in moderate grade of gastric carcinoma (MACC1 ×400). c Control gastric epithelial cells
expressing KAI1 in the membrane and cytoplasm. d Moderate grade of gastric carcinoma cells not expressing KAI1 (KAI1 ×400) (b and d are the same
GAC patient’s slice)
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in GAC tissues than that in the control tissues. Further-
more, MACC1 expression was positively correlated with
tumor size, grade, invasion of depth, LNM, and TNM
stage. Our results were consistent with those of pre-
vious studies in GAC [8, 31–33] demonstrating that
MACC1 should be useful as a clinical candidate bio-
marker of GAC.
KAI1, a cell membrane protein that binds to ECM or
adhesion proteins [34, 35], is widely considered as a
suppresser gene of metastasis in many cancers [19–26].
Table 2 The association between the expression of MACC1 or KAI1 and clinicopathological characteristics in gastric
adenocarcinoma
Variable MACC1 P value KAI1 P value
Negative Positive Negative Positive
Gender 0.482 0.065
Male 82 132 118 96
Female 47 64 73 38
Ages 0.295 0.079
<58 51 89 90 50
≥58 78 107 101 84
Gross type 0.108 0.965
Polypoid 20 17 21 16
Ulcerative 80 140 130 90
Invasive 29 39 40 28
Location 0.072 0.372
Antrum 64 99 92 71
Cardia 41 77 69 49
Pylorus 24 20 30 14
Size 0.009 0.354
D < 4.0 cm 35 40 42 33
4.0 cm ≤ D < 8.0 cm 87 124 122 89
8.0 cm ≤ D 7 32 27 12
Depth of invasion <0.001 <0.001
Submucosa 13 8 9 12
Subserosa 53 47 43 57
Visceral peritoneum 59 125 122 62
Adjacent structures 4 16 17 3
Tumor grade 0.009 0.045
Well 20 27 21 26
Moderate 91 113 120 84
Poor 18 56 50 24
Lymph node metastasis <0.001 0.016
No 93 85 94 84
Yes 36 111 97 50
TNM stage <0.001 <0.001
I and II 96 57 71 82




aNegative relationship (r = −0.240, P < 0.001)
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KAI1 has been correlated with carcinogenesis [20]
and showed to predict a poor metastasis and progno-
sis [19–26]. In this study, we also found that KAI1
expression was significantly related to tumor grade,
invasion of depth, LNM, and TNM stage. In addition,
Kaplan-Meier survival analysis indicated that GAC pa-
tients with positive KAI1 expression had significantly
increased survival time compared to those with nega-
tive KAI1. These results indicated that KAI1 should
play a key role in tumorigenesis, invasion, metastasis,
and prognosis of GAC. Several other immunohisto-
chemical studies that investigated the metastatic and
prognostic significance of KAI1 in GAC patients
obtained similar results [24, 36, 37]. Thus, our results
supported the conception that KAI1 should be a
credible biomarker of GAC, especially for predicting
metastasis and prognosis of cancers.
Metastasis and recurrence are the most common
reasons of cancer-related deaths in GAC. TNM staging
system is well-known as the guide for devising therapeutic
strategies for patients with GAC. However, the TNM
staging system cannot provide comprehensive information
about the biological behavior of the cancer. Thus, it is ur-
gent to seek novel and effective metastatic and prognostic
biomarkers to predict biological behavior (metastasis and
recurrence) in GAC patients. In our study, multivariate
Cox model analysis showed that the positive expression of
either MACC1 or KAI1, as well as TNM stage, was an in-
dependent prognostic indicator for patients with GAC.
In our study, we found that MACC1 expression was
negatively correlated with KAI1 expression. Furthermore,
we also found that there was a negative correlation between
the high expression of MACC1 and low expression of
KAI1 in the same GAC patient. Abnormal (decreased or
lost) expression of KAI1 may be involved in the initiation,
development, invasion, metastasis, and recurrence of GAC
through lost of function of tumor suppressor gene or
suppressor gene of tumor metastasis. Indeed, KAI1, as a
suppressor of tumor metastasis, could inhibit β-catenin
tyrosine phosphorylation and stabilize E-cadherin-β-catenin
complexes to suppress tumor metastasis [38]. In addition,
KAI1 could inhibit the process of β-catenin-mediated EMT
to prevent tumor angiogenesis and lymphangiogenesis [39].
Meanwhile, MACC1 could be bound to the promoter of
the MET gene and activate the HGF/MET signaling path-
way to promote cancer cell proliferation, invasion, and me-
tastasis [3, 4]. Furthermore, it could promote angiogenesis
and lymphangiogenesis to lead to cancer cell invasion and
metastasis [40, 41]. Moreover, KAI1 is able to be bind to c-
MET to form a complex or quench the activation of HGF,
thus preventing the activation of MACC1 to inhibit the mi-
gration of tumor cells [42, 43]. Decreased or lost expression
of KAI1 might lose inhibiting the activation of MACC1,
angiogenesis and lymphangiogenesis, and stabilization of E-
cadherin-β-catenin complexes to promote cancer cell inva-
sion and metastasis. At the same time, abnormal expression
of MACC1 could further promote cancer cell invasion and
metastasis. However, the methodology of subjects in our
study was relatively simple; further studies with more
methodologies (such as assessing the effect of target
molecules on biological properties in vitro and in vivo
models) are needed to verify the present observation.
Fig. 2 Kaplan-Meier survival analysis by MACC1 and KAI1 status. The y-axis represents the percentage of patient; the x-axis, their survival in
months. The green line represents patients with positive expression of MACC1 (a) or KAI1 (b) with a trend of worse or better survival time than
the blue line representing the negative MACC1 group or KAI1 group (P < 0.001). Mean survival time was 32.7 months for the positive expression
of the MACC1 group and 56.1 months for the negative MACC1 group. Mean survival time was 52.6 months for the positive expression of the
KAI1 group and 34.5 months for the negative KAI1 group (n = 325)
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Conclusions
Our findings indicate that abnormal expression of MACC1
and KAI1 should play key roles in the development of
GAC. The combined detection of MACC1 and KAI1 may
be valuable as biomarkers for metastasis and thereby prog-
nosis for patients with GAC.
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transition; OS: Overall survival; TM4SF: Transmembrane 4 superfamily;
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Table 3 Results of univariate analyses of overall survival (OS)
time
Variable n Mean OS (months) Log-rank P value
MACC1 46.375 <0.001
Negative 129 56.1 ± 22.3
Positive 196 32.7 ± 24.5
KAI1 25.422 <0.001
Negative 191 34.5 ± 25.6
Positive 134 52.6 ± 23.4
Gender 0.187 0.666
Male 214 42.5 ± 26.2
Female 111 41.0 ± 26.5
Ages 0.420 0.517
< 58 140 41.6 ± 27.2
≥ 58 185 42.3 ± 25.6
Gross type 0.541 0.763
Polypoid 37 46.3 ± 26.8
Ulcerative 220 41.7 ± 26.1
Invasive 68 40.5 ± 26.5
Location 5.536 0.063
Antrum 163 41.4 ± 26.5
Cardia 118 44.3 ± 26.7
Pylorus 44 37.9 ± 23.8
Size 6.844 0.033
D < 4.0 cm 75 49.8 ± 27.8
4.0 cm ≤ D < 8.0 cm 211 40.0 ± 25.5
8.0 cm ≤ D 39 38.4 ± 25.0
Depth of invasion 26.806 <0.001
Submucosa 21 64.1 ± 16.7
Subserosa 100 50.6 ± 27.1
Visceral peritoneum 184 35.8 ± 24.3
Adjacent structures 20 32.5 ± 23.6
Tumor grade 2.576 0.276
Well 47 47.0 ± 32.6
Moderate 204 40.8 ± 24.3
Poor 74 42.0 ± 26.9
LNM 75.925 <0.001
No 178 53.4 ± 24.1
Yes 147 28.2 ± 21.8
TNM stage 158.587 <0.001
I and II 153 60.9 ± 18.1
III and IV 172 25.2 ± 20.2
Table 4 Results of multivariate analyses of overall survival (OS)
time
Covariate B SE P HR 95 % CI
TNM stage 1.277 0.181 <0.001 3.585 2.513–5.112
MACC1 0.385 0.150 0.010 1.470 1.096–1.972
KAI1 −0.434 0.141 0.002 0.648 0.492–0.854
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